A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.

Conditions

Hyperoxaluria
Nonalcoholic Fatty Liver Disease
Kidney Stone

Interventions

DRUG: BMN 255
DRUG: Placebo

Sponsor

BioMarin Pharmaceutical